Claudin-4 as a Marker in Prostate Cancer
Author Information
Author(s): Landers K A, Samaratunga H, Teng L, Buck M, Burger M J, Scells B, Lavin M F, Gardiner R A
Primary Institution: University of Queensland
Hypothesis
This study aimed to correlate the use of potential biomarkers of prostate cancer primary lesions with metastases.
Conclusion
Claudin-4 is significantly overexpressed in both primary and metastatic prostate cancer, suggesting its potential as a diagnostic and therapeutic target.
Supporting Evidence
- Claudin-4 was significantly upregulated in prostate cancer specimens compared to benign prostatic hyperplasia.
- Claudin-4 expression was prominent in metastatic tissues from various sites.
- Lower grade prostate cancers exhibited higher claudin-4 expression than higher grade cancers.
Takeaway
Claudin-4 is a protein that can help doctors tell if prostate cancer is present and how aggressive it might be.
Methodology
The study used cDNA microarrays, real-time RT-PCR, western blotting, and immunohistochemistry to analyze claudin-4 expression in prostate cancer tissues.
Potential Biases
Potential bias in sample selection and the interpretation of immunohistochemical results.
Limitations
The study did not explore the regulatory mechanisms of claudin-4 expression in detail.
Participant Demographics
Patients with prostate cancer, benign prostatic hyperplasia, and high-grade prostatic intraepithelial neoplasia.
Statistical Information
P-Value
0.00001
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website